Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2011-07-05
2011-07-05
Graser, Jennifer E (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S185100, C424S239100, C424S247100, C530S350000
Reexamination Certificate
active
07972604
ABSTRACT:
The present invention discloses attenuatedClostridium perfringensorganisms that express a substantially nontoxic alpha-toxin. The expressed alpha-toxin is a deletion mutein that relative to the alpha-toxin of the mature alpha-toxin ofClostridium perfringensstrain 13, is missing at least nine consecutive amino acid residues including His68. The present invention also discloses attenuated organisms that encode the muteins, as well as the use of such attenuated organisms as vaccines.
REFERENCES:
patent: 4292307 (1981-09-01), Zemlyakova
patent: 5817317 (1998-10-01), Titball et al.
patent: 5851827 (1998-12-01), Titball et al.
patent: 6403094 (2002-06-01), Titball et al.
patent: 6610300 (2003-08-01), Segers et al.
patent: 2006/0233825 (2006-10-01), Jayappa et al.
patent: 1 483 042 (1977-08-01), None
patent: WO 02/07741 (2002-01-01), None
Alape-Girón et al., “Identification of residues critical for toxicity inClostridium perfringensphospholipase C, the key toxin in gas gangrene”,Eur. J. Biochem. 267:5191-5197 (2000).
Allen and Blaschek, “Electroporation-induced transformation of intact cells ofClostridium perfringens”, Applied and Environmental Microbiology, 54(9);2322-2324 (1988).
Al-Sheikhly and Truscott, “The Interaction ofClostridium perfringensand its Toxins in the production of Necrotic Enteritis of Chickens”,Avian Dis. 21(2):256-263 (1977).
Bannam and Rood, “Clostridium perfringens-Escherichia coliShuttle Vectors That Carry Single Antibiotic Resistance Determinants”,Plasmid229:233-235 (1993).
Bennett et al., “Recombinant Vaccinia Viruses Protect AgainstClostridium perfringensα-Toxin”,Viral Immunol. 12(2):97-105 (1999).
Ficken and Wages, “Clostridial Diseases. Necrotic Enteritis”,Diseases of Poultry, 10th Ed., pp. 261-264 (1997).
Justin et al., “The First Strain ofClostridium perfringensIsolated from an Avian Source Has an Alpha-Toxin with Divergent Structural and Kinetic Properties”,Biochemistry41(20):6253-6262 (2002).
Kim et al., “Construction of anEscherichia coli-Clostridium perfringensshuttle vector and plasmid transformation ofClostridium perfringens”, Appl Environ Microbiol55(2):360-365 (1989).
Logan et al., “Epitope mapping of the alpha-toxin ofClostridium perfringens”, Infection and Immunity, 59(12):4338-4342 (1991).
Lovland and Kaldhusdal, “Severely impaired production performance in broiler flocks with high incidence ofClostridium perfringens-associated hepatitis”,Avian Pathology30:73-81 (2001).
Lovland et al., “Maternal vaccination against subclinical necrotic enteritis in broilers”,Avian Pathology33(1):83-92 (2004).
Lyras et al., “Short Communication. Conjugative Transfer of RP4-oriTShuttle Vectors fromEscherichia coiltoClostridium perfringens”, Plasmid39(2):160-164 (1998).
Matsushita et al., “AClostridium perfringensVector for the Selection of Promoters”,Plasmid31(3):317-319 (1994).
Nagahama etal., “Site-directed mutagenesis of histidine residues inClostridium perfringensalpha-toxin”,J. Bacteriology177(5): 1179-1185 (1995).
Nagahama et al., “Site-specific mutagenesis ofClostridium perfringensalpha-toxin: replacement of Asp-56, Asp-130, or Glu-152 causes loss of enzymatic and hemolytic activities”,Infect. and Immun. 65(8):3489-3492 (1997).
Pearson et al., “Hemorrhagic enteritis caused byClostridium perfringenstype C in a foal”,J. Am. Vet. Med. 188(11):1309-1310 (1986).
Roberts et al., “Development of a new shuttle plasmid system forEscherichia coliandClostridium perfringens”, Appl Env Mircobiol54(1):268-270 (1988).
Schoepe et al., “Naturally OccurringClostridium perfringensNontoxic Alpha-Toxin Variant as a Potential Vaccine Candidate against Alpha-Toxin-Associated Diseases”,Infect. and Immun. 69(11):7194-7196 (2001).
Schoepe et al., “Immunization with an alphatoxin variant 121A/91-R212H protects mice againstClostridium perfringensalphatoxin”,Anaerobe12(1):44-48 (2006).
Sloan et al., “Construction of a sequencedClostridium perfringens-Escherichia colishuttle plasmid”,Plasmid27(3):207-219 (1992).
Stevens et al., “Immunization with the C-domain of alpha-toxin prevents lethal infection, localizes tissue injury, and promotes host response to challenge withClostridium perfringens”, Journal of Infectious Diseases, 190(4):767-773 (2004).
Tsutsui et al., “Phylogenetic Analysis of Phospholipase C Genes fromClostridium perfringensTypes A to E andClostridium novyi”, Journal of Bacteriology, 177(24):7164-7170 (1995).
Williamson and Titball, “A genetically engineered vaccine against the alpha-toxin ofClostridium perfringensprotects mice against experimental gas gangrene”,Vaccine11(12):1253-1258 (1993).
International Search Report dated Jan. 22, 2008, for corresponding International Application No. PCT/US2007/009135; Applicant: Schering-Plough Ltd.
Cochran Mark D.
Lair Stephen V.
Peterson Gary R.
Synenki Richard M.
Graser Jennifer E
Intervet Inc.
LandOfFree
Recombinant attenuated clostridium organisms and vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant attenuated clostridium organisms and vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant attenuated clostridium organisms and vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2720847